
EyePoint Pharmaceuticals (EYPT)
Order type
Buy in
Order amount
Est. shares
0 shares
Buy EyePoint Pharmaceuticals (EYPT) Stock
Start investing in EyePoint Pharmaceuticals (EYPT)
About EyePoint Pharmaceuticals (EYPT)
Market cap | $621.37M |
Today's volume | 822.47K |
Revenue (TTM) | $56.04M |
Avg. daily volume | 831.65K |
EBITDA (TTM) | -$159.64M |
Open | $8.61 |
Price / earnings ratio | -3.75x |
Today's range | $8.5 - $9.04 |
Debt / equity | 8.07x |
52 week range | $3.91 - $13.99 |
5 year debt / equity | 56.72x |
Beta (LTM) | 1.46x |
Interest coverage | -10418.14x |
Dividend & yield | $0.00 (0.00%) |
Current ratio | 7.85x |
Ex-dividend date | — |
Next earnings | Aug 6, 2025 |
Dividend payable date | — |
EyePoint Pharmaceuticals Stock Rating
EyePoint Pharmaceuticals Stock News
View all



Frequently Asked Questions (FAQ)
How to buy EYPT stock on Public
- 1
Sign up for a brokerage account on Public
It’s easy to get started. You can sign up for an account directly on our website or by downloading the Public app for iOS or Android.
- 2
Add funds to your Public account
There are multiple ways to fund your Public account—from linking a bank account to making a deposit with a debit card or wire transfer.
- 3
Choose how much you'd like to invest in EYPT stock
Navigate to the Explore page. Then, type EYPT into the search bar. When you see EYPT stock appear in the results, tap it to open up the purchase screen.
- 4
Manage your investments in one place
You can find your newly purchased EYPT stock in your portfolio—alongside the rest of your stocks, ETFs, crypto, treasuries, and alternative assets.
EyePoint Pharmaceuticals Stock Earnings
The value each EYPT share was expected to gain vs. the value that each EYPT share actually gained.
EyePoint Pharmaceuticals (EYPT) reported Q1 2025 earnings per share (EPS) of -$0.65, missing estimates of -$0.55 by 18.18%. In the same quarter last year, EyePoint Pharmaceuticals's earnings per share (EPS) was -$0.55. EyePoint Pharmaceuticals is expected to release next earnings on 08/06/2025, with an earnings per share (EPS) estimate of $0.